drugset / Trial / NCT01613040

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

NCT01613040

Phase 1 Completed 169 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blind

Summary

This multiple-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, parallel group study will investigate the effect of RO4917838 on the QTc interval in healthy volunteers. Healthy volunteers will be randomized to one of 4 treatment arms; Arm A: low dose of RO4917838, Arm B: high dose of RO4917838, Arm C: placebo to RO4917838 and moxifloxacin on Day 1, Arm D: placebo to RO4917838 and moxifloxacin on Day 11. The anticipated time on study treatment is 11 days.

Timeline

Start
2009-01
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject bitopertin Small molecule 30 mg Oral
Subject bitopertin Small molecule 175 mg Oral

Indications

No indication recorded.